nach oben

Journal of Nanoparticle Research

Erschienen in:

01.04.2013 | Review

Nanomedicine highlights in atherosclerosis

verfasst von: Varvara Karagkiozaki

Erschienen in: Journal of Nanoparticle Research | Ausgabe 4/2013

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config

KI-gestützte Suche

Aus

Abstract

Atherosclerosis is a multifactorial disease and many different approaches have been attempted for its accurate diagnosis and treatment. The disease is induced by a low-grade inflammatory process in the vascular wall, leading through a cascade of events to the eventual formation of atheromatous plaque and arterial stenosis. Different types of cells participate in the process making more difficult to recognize the potential cellular targets within the plaques for their effective treatment. The rise of nanomedicine over the last decade has provided new types of drug delivery nanosystems that are able to be delivered to a specific diseased site of the vessel for imaging while simultaneously act as therapeutic agents. In this paper, a review of the recent advances in nanomedicine that has provided novel insights to the disease diagnosis and treatment will be given in line with different nanotechnology-based approaches to advance the cardiovascular stents. The main complications of bare metal stents such as restenosis and of drug-eluting stents which is the late stent thrombosis are analyzed to comprehend the demand for emerging therapeutic strategies based on nanotechnology.

Vorheriger Artikel New vision to CuO, ZnO, and TiO2 nanoparticles: their outcome and effects

Nächster Artikel Advances of Ag, Cu, and Ag–Cu alloy nanoparticles synthesized via chemical reduction route

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

über 102.000 Bücher
über 537 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Finance + Banking
Management + Führung
Marketing + Vertrieb
Maschinenbau + Werkstoffe
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

über 67.000 Bücher
über 390 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Maschinenbau + Werkstoffe

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Aggarwal P, Hall JB, McLeland CB, Dobrovolskaia M, McNeil SE (2009) Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev 61:428–437. doi:10.1016/j.addr.2009.03.009 CrossRef

Alfonso F (2009) Treatment of In-stent Restenosis—Past, Present and Future. Eur Cardiol 5:74–78

Anderson TJ (1999) Assessment and treatment of endothelial dysfunction in humans. J Am Coll Cardiol 34:631–638. doi:10.1016/S0735-1097(99)00259-4 CrossRef

Antonov AS, Kolodgie FD, Munn DH, Gerrity RG (2004) Regulation of macrophage foam cell formation by αvβ3 integrin: potential role in human atherosclerosis. Am J Pathol 165:247–258. doi:10.1016/S0002-9440(10)63293-2 CrossRef

Arora HC, Jensen MP, Yuan Y, Wu AG, Vogt S, Paunesku T, Woloschak GE (2012) Nanocarriers enhance doxorubicin uptake in drug-resistant ovarian cancer cells. Cancer Res 72:769–778. doi:10.1158/0008-5472.CAN-11-2890 CrossRef

Babu RV, Mallikarjun V, Nikhat SR, Srikanth G, Theoharis S, Krueger U et al (2009) Targeting gene delivery to activated vascular endothelium using anti e/p-selectin antibody linked to PAMAM dendrimers. J Immunol Meth 343:79–90. doi:10.1016/j.jim.2008.12.005 CrossRef

Badimóna L, Vilahurb G, Padrób T (2009) Lipoproteins, platelets and atherothrombosis. Rev Esp Cardiol 62:1161–1178. doi:10.1016/S1885-5857(09)73331-6 CrossRef

Banquy X, Leclair G, Rabanel JM, Argaw A, Bouchard J-Fo, Hildgen P, Giasson S (2008) Selectins ligand decorated drug carriers for activated endothelial cell targeting. J Bioconjug Chem 19:2030–2039. doi:10.1021/bc800257m CrossRef

Bavry A, Kumbhani D, Helton T, Borek P, Mood G, Bhatt D (2006) Late Thrombosis of DES: A meta-analysis of randomized clinical trials. J Am Med 119: 1056–61. doi:10.1016/j.amjmed.2006.01.023

Bhargava B, Reddy K, Karthikeyan G, Raju R, Mishra S, Singh S (2006) A novel paclitaxel-eluting porous carbon–carbon NP coated nonpolymeric cobalt–chromium stent: evaluation in a porcine model. J Cath Cardiovasc Interv 67:698–702. doi:10.1002/ccd.20698 CrossRef

Boekhorst BC, Tilborg GA, Strijkers GJ, Nicolay K (2012) Molecular MRI of inflammation in atherosclerosis. Curr Cardiovasc Imaging Rep 5:60–68. doi:10.1007/s12410-011-9114-4 CrossRef

Briley-Saebo KC, Johansson LO, Hustvedt SO, Haldorsen AG, Bjornerud A, Fayad ZA, Ahlstrom HK (2006) Clearance of iron oxide particles in rat liver—effect of hydrated particle size and coating material on liver metabolism. Invest Radiol 41:560–571. doi:10.1097/01.rli.0000221321.90261.09 CrossRef

Burtea C, Ballet S, Laurent S, Rousseaux O, Dencausse A, Gonzalez W et al (2012) Development of a magnetic resonance imaging protocol for the characterization of atherosclerotic plaque by using vascular cell adhesion molecule-1 and apoptosis-targeted ultrasmall superparamagnetic iron oxide derivatives. Arterioscler Thromb Vasc Biol 32:e36–e48. doi:10.1161/ATVBAHA.112.245415 CrossRef

Caruthers SD, Cyrus T, Winter PM, Wickline SA, Lanza GM M (2009) Anti-angiogenic perfluorocarbon nanoparticles for diagnosis and treatment of atherosclerosis. Nanomed Nanobiotechnol 3:11–23. doi:10.1002/wnan.9

Casals E, Pfaller T, Duschl A, Oostingh GJ, Puntes V (2010) Time evolution of the nanoparticle protein corona. ACS Nano 4:3623–3632. doi:10.1021/nn901372t CrossRef

Caves JM, Chaikof EL (2006) The evolving impact of microfabrication and nanotechnology on stent design. J Vasc Surg 44:1363–1368. doi:10.1016/j.jvs.2006.08.046 CrossRef

Channon K (2002) Endothelium and pathogenesis of atherosclerosis. J Med 30:54-58. doi:http://dx.doi.org/10.2174/187152212803521011

Chaw CS, Chooi KW, Liu XM, Tan CW, Wang L, Yang YY (2004) Thermally responsive core-shell nanoparticles self-assembled from cholesteryl end-capped and grafted polyacrylamides: drug incorporation and in vitro release. Biomaterials 25:4297–4308. doi:10.1016/j.biomaterials.2003.10.095 CrossRef

Chen MS, John JM, Chew DP et al (2006) Bare metal stent restenosis is not a benign clinical entity. Am Heart J 151:1260. doi:10.1016/j.ahj.2005.08.011 CrossRef

Choi HS, Ashitate Y, Lee JH, Kim SH, Matsui A, Insin N, Bawendi MG, Semmler-Behnke M, Frangioni JV, Tsuda A (2010) Rapid translocation of nanoparticles from the lung airspaces to the body. Nat Biotech 28:1300–1303. doi:10.1038/nbt.1696 CrossRef

Chono S, Tauchi Y, Morimoto K (2006) Influence of particle size on the distributions of liposomes to atherosclerotic lesions in mice. Drug Dev Ind Pharm 32:125–135. doi:10.1080/03639040500390645 CrossRef

Chorny M, Fishbein Yellen BB, Alferiev IS, Bakay M, Ganta S, Adamo R et al (2010) Targeting stents with local delivery of paclitaxel-loaded magnetic nanoparticles using uniform fields. Proc Natl Acad Sci USA 107:8346–8351. doi:10.1073/pnas.0909506107 CrossRef

Colombo A, Iakovou I (2004) Drug-eluting stents: the new gold standard for percutaneous coronary revascularisation. Eur Heart J 25:895–897. doi:10.1016/j.ehj.2004.03.023 CrossRef

Cutlip DE, Chauhan MS, Baim DS et al (2002) Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol 40:2082–2089. doi:10.1016/S0735-1097(02)02597-4 CrossRef

Cyrus T, Zhang H, Allen JS, Williams TA, Hu G, Caruthers SD, Wickline SA, Lanza GM (2008) Intramural delivery of rapamycin with alphavbeta3-targeted paramagnetic nanoparticles inhibits stenosis after balloon injury. Arterioscler Thromb Vasc Biol 28:820–826. doi:10.1161/ATVBAHA.107.156281 CrossRef

De Graaf J, Hak-Lemmers HL, Hectors MP, Demacker PN et al (1991) Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb Vasc Biol 11:298–306. doi:10.1161/01.ATV.11.2.298 CrossRef

Dejana E (2004) Endothelial cell-to-cell junctions: happy together. Nat Rev Mol Cell Biol 5:261–270. doi::10.1038/nrm1357 CrossRef

Dell’Orco D, Lundqvist M, Oslakovic C, Cedervall T, Linse S (2010) Modeling the time evolution of the nanoparticle-protein corona in a body fluid. PLoS ONE 5:e10949. doi:10.1371/journal.pone.0010949 CrossRef

Deosarkar SP, Malgor R, Fu J, Kohn LD, Hanes J, Goetz DJ (2008) Polymeric particles conjugated with a ligand to VCAM-1 exhibit selective avid and focal adhesion to sites of atherosclerosis. J Biotechnol Bioeng 101:400–752. doi:10.1002/bit.21885 CrossRef

Douglas JS (2012) Drug-Eluting Stent Restenosis. A Need for New Technology? J Am Coll Cardiol Interv 5:738–740. doi:10.1016/j.jcin.2012.03.019

Ehrenberg MS, Friedman AE, Finkelstein JN, Oberdörster G, McGrath JL (2009) The influence of protein adsorption on nanoparticle association with cultured endothelial cells. Biomater 30:603–610. doi:10.1016/j.biomaterials.2008.09.050 CrossRef

Falk E (2006) Pathogenesis of atherosclerosis. J Am Coll Cardiol 47:7–12. doi:10.1016/jjacc.2005.09.068 CrossRef

Falk E, Prediman K, Shah PK, Fuster V (1995) Coronary plaque disruption. Circulation 92:657–671. doi:10.1161/01.CIR.92.3.657 CrossRef

Finn A, Nakazawa G, Ladich E, Kolodgie F, Virmani R (2008) Does underlying plaque morphology play a role in vessel healing after drug-eluting stent implantation? J Am Coll Cardiol Imaging 1:485–488. doi:10.1016/j.jcmg.2008.04.007

Frias JC, Williams KJ, Fisher EA, Fayad ZA (2004) Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. J Am Chem Soc 126:16316-7. doi:10.1021/ja044911a

Fulmer T (2009) Disrupting atherosclerosis. SciBX 3:79. doi:10.1038/scibx.2009.79

Garg S, Serruys P (2010) Coronary stents: current status. J Am Coll Cardiol 56:1–42. doi:10.1016/j.jacc.2010.06.007 CrossRef

Genders TS, Meijboom WB, Meijs MFL, Schuijf JD, Mollet NR, Weustink AC, Pugliese F, Bax JJ, Cramer MJ et al (2009) CT coronary angiography in patients suspected of having coronary artery disease: decision making from various perspectives in the face of uncertainty. Radiology 253:734–744. doi:10.1148/radiol.2533090507 CrossRef

Goonewardena SN (2012) Approaching the asymptote: obstacles and opportunities for nanomedicine in cardiovascular disease. Curr Atheroscler Rep 14:247–253. doi:10.1007/s11883-012-0249-9 CrossRef

Gupta AS (2011) Nanomedicine approaches in vascular disease: a review. J Nanomed 7: 763–779. doi:http://dx.doi.org/10.1016/j.nano.2011.04.001

Hansson GK (2005) Mechanisms of disease inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352:1685–1695. doi:10.1056/NEJMra043430 CrossRef

Hara H, Nakamura M, Palmaz JC, Schwartz RS (2006) Role of stent design and coatings on restenosis and thrombosis. Adv Drug Deliv Rev 58:377–386. doi:10.1016/j.addr.2006.01.022 CrossRef

Hildebrandt N, Hermsdorf D, Signorell R, Schmitz SA, Diederichsena U (2007) Superparamagnetic iron oxide nanoparticles functionalized with peptides by electrostatic interactions. Arkivoc (v): 79–90. doi:10.1039/B406193D

Hoffmann R, Mintz GS (2000) Coronary in-stent restenosis—predictors, treatment and prevention. Eur Heart J 21:1739–1749. doi:10.1053/euhj.2000.2153 CrossRef

Hoshino A, Fujioka K, Oku T et al (2004) Physicochemical properties and cellular toxicity of nanocrystal quantum dots depend on their surface modification. Nano Lett 4:2163–3163. doi:10.1021/nl048715d CrossRef

Inoue T, Croce K, Morooka T, Sakuma M, Node K, Simon DI (2011) Vascular inflammation and repair. Implications for re-endothelialization, restenosis, and stent thrombosis. J Am Coll Cardiol 10:1057–1066. doi:10.1016/j.jcin.2011.05.025

Jayagopal A, Russ P, Haselton F (2007) Surface engineering of quantum dots for in-vivo vascular imaging. J Bioconjug Chem 18:1424–1433. doi:10.1021/bc070020r CrossRef

Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R (2006) Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48: 193–202. doi:http://dx.doi.org/10.1016/j.jacc.2006.03.042

Joner M, Morimoto K, Kasukawa H, Steigerwald K, Merl S et al (2008) Site-specific targeting of nanoparticle prednisolone reduces in-stent restenosis in a rabbit model of established atheroma. Arterioscler Thromb Vasc Biol 28:1960–1966. doi:10.1161/ATVBAHA.108.170662 CrossRef

Joo J, Nam HY, Nam SH, Baek I, Park JS (2009) A novel deposition method of plga nanoparticles on coronary stents. Bull Korean Chem Soc 30:1085–1087CrossRef

Kang HW, Josephson L, Petrovsky A, Weissleder R, Bogdanov A (2002) Magnetic resonance imaging of inducible E-selectin expression in human endothelial cell culture. Bioconjug Chem 13:122–127. doi:10.1021/bc0155521 CrossRef

Karagkiozaki V, Logothetidis S, Laskarakis A, Giannoglou G, Lousinian S (2008a) AFM study of the thrombogenicity of carbon-based coatings for cardiovascular applications. J Mater Sci Eng B 152:16–21. doi:10.1016/j.mseb.2008.06.013 CrossRef

Karagkiozaki V, Logothetidis S, Lousinian S, Giannoglou G (2008) Impact of surface electric properties of carbon-based thin films on platelets activation for nano-medical and nano-sensing applications. J Int Nanomed 3:461–469. doi:http://dx.doi.org/10.2147/IJN.S3607

Karagkiozaki V, Logothetidis S, Kalfagiannis N, Lousinian S, Giannoglou G (2009) AFM probing platelets activation behavior on titanium nitride nanocoatings for biomedical applications. J Nanomed 5:64–72. doi:10.1016/j.nano.2008.07.005

Karagkiozaki V, Logothetidis S, Kassavetis S, Giannoglou G (2010) Nanomedicine for the reduction of the thrombogenicity of stent coatings. Int J Nanomed 5:239–248. doi:http://dx.doi.org/ 10.2147/IJN.S7596

Karagkiozaki V, Karagiannidis P, Kalfagiannis N, Kavatzikidou P, Patsalas P, Georgiou D, Logothetidis S (2012a) Novel nanostructured biomaterials: implications for coronary stent thrombosis. Int J Nanomed 7:6063–6076. doi:10.2147/IJN.S34320

Karagkiozaki V, Vavoulidis E, Karagiannidis PG, Gioti M, Fatouros DG, Vizirianakis IS, Logothetidis S (2012b) Development of a nanoporous and multilayer drug-delivery platform for medical implants. Int J Nanomed 7: 5327–38. doi:http://dx.doi.org/10.2147/IJN.S31185

Karagkiozaki V, Vavoulidis E, Logothetidis S (2012c) Nanomedicine pillars and monitoring nanobiointeractions. In: Logothetidis S (ed) Nanomedicine and nanobiotechnology, 1st edn. Springer-Verlag, Berlin Heidelberg, pp 27–52CrossRef

Kawasaki E, Player A (2005) Nanotechnology, nanomedicine, and the development of new, effective therapies for cancer. Nanomedicine J 1:101–109. doi:10.1016/j.nano.2005.03.002

Kolodgie FD, John M, Khurana C, Farb A, Wilson PS, Acampado E et al (2002) Sustained reduction of in-stent neointimal growth with the use of a novel systemic nanoparticle paclitaxel. Circulation 106:1195–1198. doi:10.1161/01 CrossRef

Kreylingn WG, Hirn S, Schleh C (2010) Nanoparticles in the lung. Nat Biotech 28:1275–1276. doi:10.1038/nbt.1735 CrossRef

Krol S (2012) Challenges in drug delivery to the brain: nature is against us. J Control Release 164:145–155. doi:10.1016/j.jconrel.2012.04.044 CrossRef

Lanza GM, Yu X, Winter PM, Abendschein DR, Karukstis KK, Scott MJ et al (2002) Targeted antiproliferative drug delivery to vascular smooth muscle cells with a magnetic resonance imaging nanoparticle contrast agent: implications for rational therapy of restenosis. Circulation 106:2842–2847. doi:10.1161/01.CIR.0000044020.27990.32 CrossRef

Li W, Tutton S, Vu AT, Pierchala L et al (2005) First-pass contrast-enhanced magnetic resonance angiography in humans using ferumoxytol, a novel USPIO-based blood pool agent. J Magn Reson Imaging 21:46–52. doi:10.1002/jmri.20235 CrossRef

Li D, Patel AR, Klibanov AL, Kramer CM, Ruiz M et al (2010) Molecular imaging of atherosclerotic plaques targeted to oxidized LDL receptor LOX-1by SPECT/CT and magnetic resonance. J Circ Cardiovasc Imaging 3:464–472. doi:10.1161/CIRCIMAGING.109.896654 CrossRef

Liistro F, Colombo A (2001) Late acute thrombosis after paclitaxel eluting stent implantation. Heart 86:262–264. doi:10.1136/heart.86.3.262 CrossRef

Lipinski MJ, Amirbekian V, Frias JC, Aguinaldo JG, Mani V, Briley-Saebo KC, Fuster V, Fallon JT, Fisher EA, Fayad ZA (2006) MRI to detect atherosclerosis with gadolinium-containing immunomicelles targeting the macrophage scavenger receptor. Magn Reson Med 56:601–610. doi:10.1002/mrm.20995 CrossRef

Lipinski MJ, Frias JC, Amirbekian V, Briley-Saebo KC et al (2009) Macrophage-specific lipid-based nanoparticles improve mri detection and characterization of human atherosclerosis. J Am Coll Cardiol Cardiovasc Imaging 2:637–647. doi:10.1016/j.jcmg.2008.08.009 CrossRef

Litovsky S, Madjid M, Zarrabi A, Casscells W, Willerson JT, Naghavi M (2003) Superparamagnetic iron oxide-based method for quantifying recruitment of monocytes to mouse atherosclerotic lesions in vivo. Circulation 107:1545–1549. doi:10.1161/01.CIR.0000055323.57885.88 CrossRef

Liu SQ, Tong YW, Yang YY (2005) Incorporation and in vitro release of doxorubicin in thermally sensitive micelles made from poly(N-isopropylacrylamide co-N, N-dimethylacrylamide)-b-poly(d, l-lactide-coglycolide) with varying compositions. Biomaterials 26:5064–5074CrossRef

Lobatto ME, Fayad ZA, Silvera S, Vucic E, Calcagno C, Mani V et al (2010) Multimodal clinical imaging to longitudinally assess a nanomedical anti-inflammatory treatment in experimental atherosclerosis. J Mol Pharm 7:2020–2029. doi:10.1021/mp100309y CrossRef

Lobatto ME, Fuster V, Fayad ZA, Mulder WJ (2011) Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nat Rev Drug Discov 10:835–852. doi:10.1038/nrd3578 CrossRef

Lockman PR, Koziara JM, Mumper RJ, Allen DD (2004) Nanoparticle surface charges alter blood-brain barrier integrity and permeability. J Drug Target 12:635-641. doi:10.1080/10611860400015936

Logothetidis S (2012) Nanomedicine and nanobiotechnology. Springer, Berlin HeidelbergCrossRef

Luscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC, Virmani R (2007) Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. J Circ 115:1051–1058. doi:10.1161/CIRCULATIONAHA.106.675934 CrossRef

Maguire PD, McLaughlin JA, Okpalugo TIT, Papakonstantinou P, McAdams ET et al (2005) Mechanical stability, corrosion performance and bioresponse of amorphous DLC for medical stents and guidewires. J Diam Relat Mater 14:1277–1288. doi:10.1016/j.diamond.2004.12.023 CrossRef

Maiseyeu A, Mihai G, Roy S, Kherada N, Simonetti O, Sen C, Sun Q, Parthasarathy S, Rajagopalan S (2010) Detection of macrophages via paramagnetic vesicles incorporating oxidatively tailored cholesterol ester: an approach for atherosclerosis imaging. J Nanomed 5:1341–1356. doi:10.2217/nnm.10.87 CrossRef

Marambio-Jones C, Hoek E (2010) A review of the antibacterial effects of silver nanomaterials and potential implications for human health and the environment. J Nanopart Res 12:1531–1551. doi. 10.1007/s11051-010-9900-y

McCarthy JR (2010) Multifunctional agents for concurrent imaging and therapy in cardiovascular disease. Adv Drug Deliv Rev 62:1023–30. doi:10.1016/j.addr.2010.07.004

McCarthy JR, Korngold E, Weissleder R, Jaffer AF (2010) A light-activated theranostic nanoagent for targeted macrophage ablation in inflammatory atherosclerosis. Small 6:2041–2049. doi:10.1002/smll.201000596 CrossRef

Mehran R, Dangas G, Abizaid AS S, Mintz GS, Lansky AJ, Satler LF et al (1999) Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. J Circ 100:1872–1878. doi:10.1161/01.CIR.100.18.1872 CrossRef

Minchin RF, Martin DJ (2010) Nanoparticles for molecular imaging—an overview. Endocrinology 151:474–481. doi:10.1210/en.2009-1012 CrossRef

Mishkel GJ, Moore AL, Markwell S et al (2007) Long-term outcomes after management of restenosis or thrombosis of drug-eluting stents. J Am Coll Cardiol 49:181–184. doi:10.1016/j.jacc.2006.08.049 CrossRef

Monopoli MP, Walczyk D, Campbell A, Elia G, Lynch I, Bombelli FB, Dawson KA (2011) Physical–chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. J Am Chem Soc 133:2525–2534. doi:10.1021/ja107583h CrossRef

Morris JB, Olzinski AR, Bernard RE, Aravindhan K, Mirabile RC, Boyce R et al (2008) p38 MAPK inhibition reduces aortic ultrasmall superparamagnetic iron oxide uptake in a mouse model of atherosclerosis: mRI assessment. Arterioscler Thromb Vasc Biol 28:265–271. doi:10.1161/ATVBAHA.107.151175 CrossRef

Mura S, Couvreur P (2012) Nanotheranostics for personalized medicine. Adv Drug Deliv Rev 64:1394–1416. doi:10.1016/j.addr.2012.06.006 CrossRef

Nahrendorf M, Jaffer FA, Kelly KA, Sosnovik DE, Aikawa E, Libby P, Weissleder R (2006) Non-invasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. J Circ 114:1504–1511. doi:10.1161/CIRCULATIONAHA.106.646380 CrossRef

Nakano K, Egashira K, Masuda S, Funakoshi K, Zhao G, Kimura S et al (2009) Formulation of nanoparticle-eluting stents by a cationic electrodeposition coating technology efficient nano-drug delivery via bioabsorbable polymeric nanoparticle-eluting stents in porcine coronary arteries. J Am Coll Cardiol Interv 2:277–283. doi:10.1016/j.jcin.2008.08.023

Nakazawa G, Finn AV, Joner M, Ladich E et al (2008) Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. J Circ 118:1138–1145. doi:10.1161/CIRCULATIONAHA.107.762047 CrossRef

O’Brien B, Carrolla W (2009) The evolution of cardiovascular stent materials and surfaces in response to clinical drivers: a review. Acta Biomater 5:945–958. doi:10.1016/j.actbio.2008.11.012 CrossRef

Pache J, Kastrati A, Mehilli J et al (2003) Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol 41:1283–1288. doi:10.1016/S0735-1097(03)00119-0 CrossRef

Panyama J, Labhasetwar V (2003) Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 55:329–347. doi:10.1016/j.addr.2012.09.023 CrossRef

Peters D, Kastantin M, Kotamraju VK, Karmali PP, Gujraty K, Tirrell M, Ruoslahti E (2009) Targeting atherosclerosis by using modular, multifunctional micelles. Proc Natl Acad Sci USA 106:9815–9819. doi:10.1073/pnas.0903369106

Potineni A, Lynn DM, Langer R, Amiji MM (2003) Poly(ethylene oxide)-modified poly(b-amino ester) nanoparticles as a pH-sensitive biodegradable system for paclitaxel delivery. J Control Release 86:223–234. doi:10.1016/S0168-3659(02)00374-7 CrossRef

Rizzo M, Berneis K (2006) Low-density lipoprotein size and cardiovascular risk assessment. QJM 99:1–14. doi:10.1093/qjmed/hci154 CrossRef

Salata O (2004) Applications of nanoparticles in biology and medicine. J Nanobiotech 2:1–6. doi:10.1186/1477-3155-2-3 CrossRef

Sanhai WR, Sakamoto JH, Canady R, Ferrari M (2008) Seven challenges for nanomedicine. Nat Nanotech 3:242–244. doi:10.1038/nnano.2008.114 CrossRef

Schmehl J, Harder C, Hans P, Wendel H, Claus D, Claussen C, Tepe G (2008) Silicon carbide coating of nitinol stents to increase antithrombogenic properties and reduce nickel release. J Card Revasc Med 9:255–262. doi:10.1016/j.carrev.2008.03.004 CrossRef

Sheridan P, Crossman D (2002) Critical review of unstable angina and non-ST elevation myocardial infarction. Postgrad Med J 78:717–726. doi:10.1136/pmj.78.926.717 CrossRef

Song CX, Labhasetwar V, Murphy H, Qu X, Humphrey WR, Shebuski RJ, Levy RJ (1997) Formulation and characterization of biodegradable nanoparticles for intravascular local drug delivery. J Control Release 43:197–212. doi:10.1016/S0168-3659(96)01484-8 CrossRef

Soppimath KS, Tan DCW, Yang YY (2005) pH-Triggered thermally responsive polymer core-shell nanoparticles for drug delivery. Adv Mater 17:318–323. doi:10.1002/adma.200401057 CrossRef

Sousa JE, Costa MA, Abizaid A et al (2003) Sirolimus-eluting stent for the treatment of in-stent restenosis: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. J Circ 107:24–27. doi:10.1161/01.CIR.0000047063.22006.41 CrossRef

Southworth R, Kaneda M, Chen J, Zhang L, Zhang H, Yang X, et al (2009) Renal vascular inflammation induced by Western diet in ApoE-null mice quantified by 19F NMR of VCAM-1 targeted nanobeacons. Nanomedicine 5:359–367. doi:10.1016/j.nano.2008.12.002

Stone G, Moses J, Ellis S, Schofer J, Dawkins K, Morice M, Colombo A et al (2007) Safety and efficacy of sirolimus and paclitaxel-eluting stents. J N Engl Med 356:998–1008. doi:10.1056/NEJMoa067193 CrossRef

Tang TY, Muller KH, Graves MJ, Li ZY, Walsh SR, Young V, Sadat U et al (2009a) Iron oxide particles for atheroma imaging. Arterioscler Thromb Vasc Biol 29:1001–1008. doi:10.1161/ATVBAHA.108.165514 CrossRef

Tang TY, Howarth SP, Miller SR, Graves MJ, Patterson AJ, et al (2009b) The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Evaluation using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in carotid disease. J Am Coll Cardiol 53:2039–50. doi:10.1016/j.jacc.2009.03.018

Tang J, Lobatto ME, Read JC, Mieszawska AJ, Fayad ZA, Mulder WJM (2012) Nanomedical theranostics in cardiovascular disease. J Curr Cardiovasc Imaging Rep 5:19–25. doi:10.1007/s12410-011-9120-6 CrossRef

Tassa C, Shaw SY, Weissleder R (2011) Dextran-coated iron oxide nanoparticles: a versatile platform for targeted molecular imaging, molecular diagnostics and therapy. Acc Chem Res 44:842–852. doi:10.1021/ar200084x CrossRef

Tenzer S, Docter D, Rosfa S, Wlodarski A, Kuharev J, Rekik A, Knauer SK, Bantz C, Nawroth T, Bier C et al (2011) Nanoparticle size is a critical physicochemical determinant of the human blood plasma corona: a comprehensive quantitative proteomic analysis. ACS Nano 5:7155–7167. doi:10.1021/nn201950e CrossRef

Tong S, Hou S, Zheng Z, Zhou J, Bao G (2010) Coating optimization of superparamagnetic iron oxide nanoparticles for high T2 relaxivity. Nano Lett 10:4607–4613. doi:10.1021/nl102623x CrossRef

Trivedi RA, Mallawarachi C, Graves MJ, Horsley J et al (2006) Identifying inflamed carotid plaques using in vivo USPIO-enhanced MR imaging to label plaque macrophages. Arterioscler Thromb Vasc Biol 26:1601–1606. doi:10.1161/01.ATV.0000222920.59760.df CrossRef

Tu C, Ng TS, Sohi HK, Palko HA et al (2011) Receptor-targeted iron oxide nanoparticles for molecular MR imaging of inflamed atherosclerotic plaques. Biomaterials 29:7209–7216. doi:10.1016/j.biomaterials.2011.06.026 CrossRef

Ungvari Z, Kaley G, De Cabo R, Sonntag WE, Csiszar A (2010) Mechanisms of vascular aging: new perspectives. J Gerontol A Biol Sci Med Sci 65A(10):1028–1041. doi:10.1093/gerona/glq113 CrossRef

Uwatoku T, Shimokawa H, Abe K, Matsumoto Y, Hattori T, Oi K et al (2003) Application of nanoparticle technology for the prevention of restenosis after balloon injury in rats. Circ Res 92:e62–e69. doi:10.1161/01.RES.0000069021.56380.E2 CrossRef

Van der Wal AC, Becker AE (1999) Atherosclerotic plaque rupture—pathologic basis of plaque stability and instability. Cardiovasc Res 41(2):334–344. doi:10.1016/S0008-6363(98)00276-4 CrossRef

Vizirianakis IS, Fatouros DG (2012) Personalized nanomedicine: paving the way to the practical clinical utility of genomics and nanotechnology advancements. Adv Drug Deliv Rev 64:1359–1362. doi:10.1016/j.addr.2012.09.034 CrossRef

Vroman L, Adams AL, Fischer GC, Munoz PC (1980) Interaction of high molecular weight kininogen, factor XII, and fibrinogen in plasma at interfaces. Blood 55:156–159

Wang YX, Hussain SM, Krestin GP (2011) Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol 11:2319–2331. doi:10.3978/j.issn.2223-4292.2011.08.03 CrossRef

Watanabe T, Haraoka S, Shimokama T (1996) Inflammatory and immunological nature of atherosclerosis. Int J Cardiol 54:S51–S60. doi:10.1016/S0167-5273(96)88773-0 CrossRef

Wickline SA, Neubauer AM, Winter P, Caruthers S, Lanza G, Samuel A (2006) Applications of nanotechnology to atherosclerosis, thrombosis, and vascular biology. Arterioscler Thromb Vasc Biol 26:435–441. doi:10.1161/01.ATV.0000201069.47550.8b CrossRef

Winter PM, Caruthers SD, Kassner A et al (2003) Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel αvβ3 -targeted nanoparticle and 1.5 tesla magnetic resonance imaging. J Cancer Res 63:5838–5843

Winter PM, Caruthers SD, Lanza GM, Wickline SA (2010) Quantitative cardiovascular magnetic resonance for molecular imaging. J Cardiovasc Magn Reson 12:62. doi:10.1186/1532-429X-12-62 CrossRef

Yancy AD, Olzinski AR, Hu TC, Lenhard SC, Aravindhan K, Gruver SM, Jacobs PM, Willette RN, Jucker BM (2005) Differential uptake of ferumoxtran-10 and ferumoxytol, ultrasmall superparamagnetic iron oxide contrast agents in rabbit: critical determinants of atherosclerotic plaque labeling. J Magn Reson Imaging 21:432–442. doi:10.1002/jmri.20283 CrossRef

Yang Y, Wang Y, Powell R, Chan P (2006) Polymeric core-shell nanoparticles for therapeutics. Clin Exp Pharmacol Physiol 33:557–562. doi:10.1111/j.1440-1681.2006.04408.x CrossRef

Yu MK, Park J, Jon S (2012) Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics 2:3–44. doi:10.7150/thno.3463 CrossRef

Zhang L, Webster T (2009) Nanotechnology and nanomaterials: promises for improved tissue regeneration. Nano Today 4:66–80. doi:10.1016/j.nantod.2008.10.014 CrossRef

Zweers MLT, Engbers GHM, Grijpma DW, Feijen J (2006) Release of anti-restenosis drugs from poly (ethylene oxide)-poly (dl-lactic-co-glycolic acid) nanoparticles. J Control Release 114: 317–324. http://dx.doi.org/10.1016/j.jconrel.2006.05.021

Titel: Nanomedicine highlights in atherosclerosis
verfasst von: Varvara Karagkiozaki
Publikationsdatum: 01.04.2013
Verlag: Springer Netherlands
Erschienen in: Journal of Nanoparticle Research / Ausgabe 4/2013
Print ISSN: 1388-0764
Elektronische ISSN: 1572-896X
DOI: https://doi.org/10.1007/s11051-013-1529-1

Premium Partner

Marktübersichten

Die im Laufe eines Jahres in der „adhäsion“ veröffentlichten Marktübersichten helfen Anwendern verschiedenster Branchen, sich einen gezielten Überblick über Lieferantenangebote zu verschaffen.

Zur Marktübersicht

Springer Professional

Abstract

Bitte loggen Sie sich ein, um Zugang zu Ihrer Lizenz zu erhalten.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Springer Professional "Technik"

Weitere Artikel der Ausgabe 4/2013

Enhanced microwave shielding and mechanical properties of high loading MWCNT–epoxy composites

A novel solvothermal route for obtaining strontium titanate nanoparticles

Aggregation of dipolar molecules in SiO2 hybrid organic–inorganic films: use of silver nanoparticles as inhibitors of molecular aggregation

Control growth of single crystalline ZnO nanorod arrays and nanoflowers with enhanced photocatalytic activity

Fe3Si nanoparticles for alternating magnetic field heating

Gas sensor based on photoconductive electrospun titania nanofibres operating at room temperature

Premium Partner

Marktübersichten